530159-35-4

Upstream product

• 426225-69-6 (1S,3R)-1-hydroxy-3-(ethyl-carboxymethoxy)-4-cyclopentene 
• 62-23-7 4-nitro-benzoic acid 
• 60410-16-4 (1R,4S)-4-hydroxy-2-cyclopentene-1-yl acetate 
• 120520-91-4 (1R,4S)-4-(tert-butyldimethylsilyloxy)cyclopent-2-enol 
• 115074-49-2 (1R,4S)-4-[(tert-butyldimethylsilyl)oxy]-2-cyclopentene-1-yl acetate 
• 530159-34-3 [(1R,4S)-4-(tert-Butyl-dimethyl-silanyloxy)-cyclopent-2-enyloxy]-acetic acid ethyl ester 

Relevant academic research and scientific papers

Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases

The invention concerns pharmaceutical compositions that contain a compound or compounds that can effectively regulate the activity of Type 5 Adenylyl Cyclase and methods for treatment of neurological diseases and disorders, as well as motor function loss

Hydroxamate based inhibitors of adenylyl cyclase. Part 2: The effect of cyclic linkers on P-site binding

The adenylyl cyclases (ACs) are a family of enzymes that are key elements of signal transduction by virtue of their ability to convert ATP to cAMP. The catalytic mechanism of this transformation proceeds through initial binding of ATP to the purine bindin